Adjuvant therapy in intermediate-stage hepatocellular carcinoma Cancer
Conditions
Interventions
This single-centre retrospective cohort study aims to evaluate the effectiveness of TACE combined with Lenvatinib plus Programmed Death-1 Inhibitors therapy in patients with intermediate-stage HCC who
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with intermediate-stage HCC undergoing curative LR. 2. Patients who received TACE alone or Lenvatinib+ PD-1 inhibitors +TACE 3. Child-Pugh class A or B that could improve to class A after treatment
Exclusion criteria
Exclusion criteria: 1. Patients who received any other adjuvant protocols 2. Without complete clinical data 3. Lost to Follow-up 4. Patients who died within three months post-surgery 5. A history of other malignancies or recurrent HCC.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-Free Survival (RFS), defined as the time from the date of curative resection to the date at which HCC recurred, measured using retrospective patient data at one timepoint | — |
Secondary
| Measure | Time frame |
|---|---|
| The following secondary outcome measures were assessed using retrospective patient data at one timepoint: 1. Overall survival, defined as the period from the time of surgery to the point of death due to hepatocellular carcinoma 2. Safety in patients who received TAP treatment according to National Cancer Institute Common Toxicity Criteria Adverse Events (CTCAE) version 5.0 | — |
Countries
China
Contacts
Public ContactGuanhua Chen
Outcome results
None listed